Recognition of the Thomsen-Friedenreich Pancarcinoma Carbohydrate Antigen by a Lamprey Variable Lymphocyte Receptor*

Received for publication, April 30, 2013, and in revised form, June 13, 2013 Published, JBC Papers in Press, June 19, 2013, DOI 10.1074/jbc.M113.480467

Ming Luo‡§1,2**, C. Alejandro Velikovsky**‡¶1 **Xinbo Yang**‡¶**, Maqbool A. Siddiqui , Xia Hong******, Joseph J. Barchi, Jr. , Jeffrey C. Gildersleeve , Zeev Pancer******, and Roy A. Mariuzza**‡¶3

From the ‡ *University of Maryland Institute for Bioscience and Biotechnology Research, W. M. Keck Laboratory for Structural Biology, Rockville, Maryland 20850,* § *Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China,* ¶ *Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland 20742, Chemical Biology Laboratory, Center for Cancer Research, NCI, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, and* ***Institute of Marine and Environmental Technology and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21202*

Background: Variable lymphocyte receptors (VLRs) bind tumor-associated carbohydrates, such as Thomsen-Friedenreich antigen (TF α), with high selectivity.

Results: The crystal structure of a VLR-TF α complex coupled with thermodynamic analysis revealed the basis for selectivity. **Conclusion:** VLRs utilize leucine-rich repeats to recognize glycans with affinity comparable to that of lectins and antibodies. **Significance:** The VLR-TF α structure provides a template for engineering VLRs to bind biomedically relevant glycans.

Variable lymphocyte receptors (VLRs) are leucine-rich repeat proteins that mediate adaptive immunity in jawless vertebrates. VLRs were recently shown to recognize glycans, such as the tumor-associated Thomsen-Friedenreich antigen (TF; $\mathsf{Gal}\beta\mathsf{1}\text{--}3\mathsf{Gal} \mathsf{N} \mathsf{A}\mathsf{c} \alpha$), with a selectivity rivaling or exceeding that **of lectins and antibodies. To understand the basis for TF recognition by one such VLR (VLRB.aGPA.23), we measured thermodynamic parameters for the binding interaction and determined the structure of the VLRB.aGPA.23-TF complex to 2.2 Å resolution. In the structure, four tryptophan residues form a** tight hydrophobic cage encasing the $TF\alpha$ disaccharide that com**pletely excludes buried water molecules. This cage together with hydrogen bonding of sugar hydroxyls to polar side chains explains the exquisite selectivity of VLRB.aGPA.23. The topology of the glycan-binding site of VLRB.aGPA.23 differs markedly from those of lectins or antibodies, which typically consist of long, convex grooves for accommodating the oligosaccharide. Instead, the TF disaccharide is sandwiched between a variable loop and the con**cave surface of the VLR formed by the β -strands of the leucine-rich **repeat modules. Longer oligosaccharides are predicted to extend** $perpendicularly$ across the β -strands, requiring them to bend to **match the concavity of the VLR solenoid.**

altered during oncogenic transformation, such that nearly all human tumors express glycoproteins with aberrant glycosylation patterns (1). These changes can affect interactions between tumor cell surface glycans and glycan binding receptors, which may determine the metastatic potential of the cancer cell. The best-studied tumor-associated carbohydrates are truncated glycans, such as T-nouvelle antigen (GalNAc α) and Thomsen-Friedenreich antigen (TF α^4 ; Gal β 1-3GalNAc α), which are linked to serine or threonine as *O*-glycans (1). These saccharides decorate mucin-type glycoproteins in \sim 90% of human cancers but are absent from nearly all normal tissues (1, 2). A number of carbohydrate binding lectins and antibodies have been developed to detect expression of T-nouvelle antigen, $TF\alpha$, and other cancer-specific glycans for diagnostic and prognostic applications (2– 4). However, most of these reagents display either broad specificity or low affinity for their target glycans and, therefore, have limited clinical utility (5, 6).

The normal processes of glycosylation are often severely

A variety of approaches have been pursued for obtaining proteins that bind cancer-specific carbohydrates and other biomedically relevant glycans with high selectivity and affinity. Most often, monoclonal antibodies are isolated from mice immunized with the glycan of interest, but this process is laborious, and most human glycans are not particularly immunogenic in mice, probably due to their conserved structures in these species, which gives rise to self-tolerance. Other strategies include directed evolution of antibodies (7) or lectins (3, 8),

^{*} This work was supported, in whole or in part, by National Institutes of Health (NIH) Grants AI036900 (to R. A. M.) and AI083892 (to Z. P.) and by the intramural research program of the NIH, NCI (to J. J. B. and J. C. G.). This work was also supported by National Science Foundation Grant MCB-0614672 (to Z. P.).

The atomic coordinates and structure factors (codes 4K79 and 4K5U) have been deposited in the Protein Data Bank (http://wwpdb.org/). ¹ Both authors contributed equally to this work.

 2 Supported by the Joint Supervision Ph.D. Project of the China Scholarship

Council. 3 To whom correspondence should be addressed: University of Maryland Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Dr., Rockville, MD 20850. Tel.: 240-314-6243; Fax: 240-314-6225; E-mail: rmariuzz@umd.edu.

⁴ The abbreviations used are: TF α , Thomsen-Friedenreich antigen; BG-H, blood group H disaccharide; BG-H3, blood group H type 3 trisaccharide; VLR, variable lymphocyte receptor; LRR, leucine-rich repeat; TF α -PAA, TF α polyacrylamide-biotin; ITC, isothermal titration calorimetry; SPR, surface plasmon resonance; LRRNT, N-terminal LRR capping module; LRRV, LRR variable module; CP, connecting peptide module; LRRCT, C-terminal LRR capping module; GPA, human glycophorin A; aGPA, asialo human glycophorin A.

Recognition of Thomsen-Friedenreich Antigen by Lamprey VLR

carbohydrate binding peptides (9), and glycan-specific aptamers (10), but none has proven generally useful.

We recently described a rapid and cost-effective strategy using yeast surface display for isolating monoclonal variable lymphocyte receptors (VLRs) from lamprey that selectively bind various human glycans, including the pancarcinoma antigens T-nouvelle antigen and TF α (11). VLRs are leucine-rich repeat (LRR) proteins that mediate adaptive immunity in jawless vertebrates (lamprey and hagfish). Although VLRs are structurally unrelated to the immunoglobulin-based antibodies of jawed vertebrates, they are able to recognize as broad a spectrum of antigens as antibodies, with entirely comparable affinity and specificity (12). VLR genes are assembled from multiple LRR-encoding cassettes by DNA recombination in a process that generates a vast repertoire of $>10^{14}$ unique receptors, which is sufficiently diverse to recognize most, if not all, antigens (13–15).

Among the lamprey VLRs isolated by screening naïve VLR libraries displayed on yeast for glycan binders was VLR-B.aGPA.23, which recognized TF α (11). Glycan array profiling showed that VLRB.aGPA.23 possessed a high degree of selectivity for $TF\alpha$. Indeed, its overall selectivity was superior to that of most lectins and antibodies (5, 6). Furthermore, a dimeric form of VLRB.aGPA.23 bound TF α with nanomolar affinity (11). In human tissue microarrays, VLRB.aGPA.23 selectively detected tumor-associated carbohydrate antigens in a variety of adenocarcinomas and squamous cell carcinomas. Moreover, lung cancer patients whose tumors stained with VLR-B.aGPA.23 experienced a significantly worse survival rate compared with patients whose tumors did not (11). Thus, highly selective VLRs such as VLRB.aGPA.23 provide a powerful means for detecting aberrantly glycosylated proteins on tumor cells, which may lead to an entirely new class of diagnostic and prognostic reagents.

Recent structural studies of VLRs bound to protein or carbohydrate ligands have begun to reveal the features that endow these LRR-based adaptive immune receptors with specificity and affinity for diverse antigens (12). However, the structural database for VLRs, which at present comprises only four VLRantigen complexes $(16–19)$, is far smaller than that for antibodies, for which hundreds of structures have been determined. Here we report the structure of VLRB.aGPA.23 bound to its tumor-associated ligand TF α . This structure, in conjunction with a thermodynamic analysis of glycan binding by this VLR, provides a basis for understanding the remarkable selectivity of VLRB.aGPA.23 at the atomic level and for engineering VLRs as highly specific reagents for recognizing tumor-associated and other biomedically important carbohydrates.

EXPERIMENTAL PROCEDURES

Glycans-Galβ1-3GalNAcα (TFα) was purchased from Toronto Research Chemicals. Galβ1-3GalNAcα-polyacrylamide-biotin (TF α -PAA) was purchased from Glycotech. Galβ1–3GalNAc α -Ser (TF α -Ser) and Galβ1–3GalNAc α -Thr $(TF\alpha-Thr)$ were prepared by deprotection of peracetylated TF-Fmoc (*N*-(9-fluorenyl)methoxycarbonyl)-Ser-OH and TF-Fmoc-Thr-OH (Sussex Research Laboratories) with sodium methoxide in methanol followed by neutralization with HCl and purification by sequential silica gel and reverse phase silica gel chromatography in 75 and 88% yields, respectively. Products were characterized by ¹H NMR and mass spectrometry. Fuc α 1–2Gal β (BG-H) was provided by the Consortium for Functional Glycomics. Human glycophorin A (GPA) was purchased from Sigma. Asialo human glycophorin A (aGPA) was prepared by desialylating GPA by mild acid treatment using 0.025 N H₂SO₄ in 0.85% NaCl for 2 h at 80 °C, then neutralized with 1 M Tris-HCl (pH 8.8) and dialyzed overnight against PBS (pH 7.4) (Quality Biological)

Protein Expression and Purification—VLRB.aGPA.23 was isolated from a VLRB library $(1.2 \times 10^8$ independent clones) generated from lymphocyte cDNA of unimmunized lampreys and displayed on the surface of yeast (11). The library was screened by alternating rounds of magnetic-activated and fluorescent-activated cell sorting with $TF\alpha$ or aGPA. The diversity region of VLRB.aGPA.23, from LRRNT to LRRCT (residues 1–219), was cloned into the expression vector pT7–7 (Novagen) and expressed as inclusion bodies in BL21-Codon-Plus(DE3)-RIL *Escherichia coli* cells (Stratagene). Bacteria were grown at 37 °C in LB medium to an absorbance of 0.6– 0.8 at 600 nm and induced with 1 mm isopropyl- β -D-thiogalactoside. After incubation for 3 h, the bacteria were harvested by centrifugation and resuspended in 50 mM Tris-HCl (pH 8.0) containing 0.1 M NaCl and 2 mM EDTA; cells were disrupted by sonication. Inclusion bodies were washed with 50 mm Tris-HCl (pH 8.0), 0.1 M NaCl, and 0.5% (v/v) Triton X-100, then solubilized in 8 M urea and 100 mM Tris-HCl (pH 8.5). For *in vitro* folding, inclusion bodies were diluted to a final concentration of 10 mg/liter into 0.8 M arginine, 100 mM Tris-HCl (pH 8.5), 2 mM EDTA, 3 mM reduced glutathione, and 0.3 mM oxidized glutathione. After 3 days at 4° C, the folding mixture was concentrated, dialyzed against 20 mm Tris-HCl (pH 8.5), and applied to a MonoQ column (GE Healthcare). Further purification was carried out using a Superdex 75 HR column.

Isothermal Titration Calorimetry—ITC measurements were carried out using a MicroCal iTC200 titration microcalorimeter. Purified VLRB.aGPA.23 was exhaustively dialyzed against 10 mm phosphate (pH 7.2), 136 mm NaCl, and 4 mm KCl. In a typical experiment, 1- or 2- μ l aliquots of 2.46–7.40 mm glycan solution were injected from a $40-\mu l$ rotating syringe into the sample cell containing 200 μ l of 0.157–0.377 mm VLR-B.aGPA.23 solution at 10 °C. For each titration experiment, an identical buffer dilution correction was conducted; these heats of dilution were subtracted from the corresponding binding experiment. Equilibrium binding constants (K_h) were obtained by non-linear least-squares fit of the ITC data to a single-site binding model. Data acquisition and analysis were performed with the software package ORIGIN.

Surface Plasmon Resonance (SPR) Analysis—All SPR binding experiments were performed at 25 °C in phosphate-buffered saline (pH 7.4) using a BIAcore T100 biosensor. Biotinylated $TF\alpha$ -PAA (33 nm), aGPA (2.8 nm), and GPA (4.6 nm) were immobilized on streptavidin-coated BIAcore SA chips followed by blocking the remaining streptavidin sites with $1 \mu M$ biotin solution. An additional flow cell was injected with only free biotin to serve as a blank control. Solutions containing different concentrations of VLRB.aGPA.23 were then serially injected

FIGURE 1. Calorimetric titrations of VLRB.aGPA.23 with glycan ligands at 10 °C. A, raw data were obtained from 48 automatic injections of 0.5- μ l aliquots of 5.02 mm TF_{α} solution into 0.370 mm VLRB.aGPA.23 solution. *B*, shown is the incremental heat per mole of added ligand (*open squares*) for the titration in *A*. The K_b obtained from this titration is 2.21 \pm 0.06 \times 10⁴ M⁻¹ with $n = 1.09 \pm 0.01$. *C*, raw data were obtained from 48 automatic injections of 0.5-_{*L*}l aliquots of 4.80 mm TF α -Ser solution into 0.370 mm VLRB.aGPA.23 solution. *D*, shown is the incremental heat per mole of added ligand (*open squares*) for the titration in *C*; $K_b = 2.04 \pm 0.06 \times 10^4$ M⁻¹ with $n = 0.97 \pm 0.10$. *E*, raw data were obtained from 19 automatic injections of 2- μ l aliquots of 7.4 mM BG-H solution into 0.310 mM VLRB.aGPA.23 solution. *F*, shown is a non-linear least-squares fit (*solid line*) of the incremental heat per mole of added ligand (*open squares*) for the titration in *E*; $K_b = 2.04 \pm 0.06 \times 10^4$ M⁻¹ with $n = 1.06 \pm 0.07$.

over the chips with immobilized ligands and the blank until SPR signals reached a plateau. Equilibrium affinity measurements were performed at different flow rates (30 – 50 μ l/min). Specific binding data were fitted with a 1:1 Langmuir binding model using BIAevaluation 4.1 software (BIAcore) to calculate K_h values.

Crystallization and Data Collection—For crystallization of the VLRB.aGPA.23-TF α complex, VLRB.aGPA.23 (15 mg/ml) was mixed with TF α -Ser in a 1:10 molar ratio. Crystals grew at 25 °C in hanging drops in 20% (w/v) polyethylene glycol (PEG) 3350, 4% (v/v) glycerol, and 0.1 M Tris-HCl (pH 7.0). Crystals of the VLRB.aGPA.23-BG-H complex grew in 28.5% (w/v) PEG 3350, 0.6 M NaCl, and 0.1 M Tris-HCl (pH 7.0) from solutions containing a 5-fold molar excess of BG-H. For data collection, both complexes were cryoprotected in 100% paraffin oil before flash-cooling. X-ray diffraction data were recorded in-house at 100 K using a Rigaku R-axis I V^{2+} image plate detector. All data were indexed, integrated, and scaled with the program Crystal-Clear (Rigaku). Both crystals contain four molecules in the asymmetric unit. Data collection statistics are summarized in Table 1.

Structure Determination and Refinement—The structure of the VLRB.aGPA.23-TF α complex was solved by molecular replacement with the Phaser program (20) using VLRB.RBC36 (PDB accession code 3E6J) (16) as a search model. Refinement was performed with RefMac 5.0 (21). Modeling and rebuilding were accomplished with COOT (22) using σ_A -weighted $2F_o$ – F_c and $F_o - F_c$ electron density maps. The structure of the VLRB.aGPA.23-BG-H complex was solved by molecular replacement with Phaser (20). The search model used in the calculations was the refined VLRB.aGPA.23-TF α structure. Final refinement statistics are presented in Table 1.

Protein Data Bank Accession Codes—Coordinates and structure factors for the VLRB.aGPA.23-TF α and VLRB.aGPA.23-BG-H complexes have been deposited under accession codes 4K79 and 4K5U, respectively.

RESULTS

Thermodynamic Analysis of GlycanBinding toVLRB.aGPA.23— We previously analyzed the binding selectivity of VLR-B.aGPA.23 using glycan microarrays (11). The main reactive structures were: TF α -Ser, blood group H type 3 trisaccharide (BG-H3; Fuc α 1–2Gal β 1–3GalNAc α), blood group H disaccharide (BG-H; Fuc α 1–2Gal β), and aGPA, which is decorated with TF α -Ser (23).

We used ITC to determine thermodynamic parameters for the binding of VLRB.aGPA.23 to TF α , TF α -Ser, TF α -Thr, BG-H, and galactose (Table 2). For this purpose, VLR-B.aGPA.23 was expressed as a soluble monomeric protein by *in vitro* folding from bacterial inclusion bodies. As measured by ITC, VLRB.aGPA.23 bound the TF α disaccharide with an equilibrium binding constant (K_b) of 2.21 \times 10⁴ M⁻¹ (Fig. 1, *A* and *B*). Importantly, this affinity is as high as has been reported for animal or plant lectin binding to disaccharide ligands (24). It is also nearly identical to the affinities determined for TF α -Ser $(K_b = 2.04 \times 10^4 \,\text{m}^{-1})$ (Fig. 1, *C* and *D*) and TF α -Thr (2.43 \times $10⁴$ M⁻¹) (see Table 2), showing that the amino acid moiety made no appreciable contribution to binding VLRB.aGPA.23, at least in solution. In terms of energetics, all three reactions were exothermic (negative ΔH_b), indicating favorable contacts between the sugars and protein. Whereas the binding of TF α and TF α -Ser was enthalpically driven, that of TF α -Thr was characterized by a large favorable entropy (positive $T\Delta S_h$),

FIGURE 2. **Equilibrium binding of VLRB.aGPA.23 to glycoconjugates.** *A*, SPR sensograms for the interaction of VLRB.aGPA.23 (267.4, 133.7, 66.8, 33.4, 26.7, 16.7, 8.3 μ M) with immobilized TF α -PAA (578 resonance units (RU)) are shown. K_b (1.5 \times 10⁴ M⁻¹) was calculated from a Scatchard plot (*inset*) after correction for nonspecific binding by measuring the concentration of free reactants and complex at equilibrium. *B*, shown is the interaction of VLRB.aGPA.23 (267.4, 133.7, 66.8, 33.4, 26.7, 16.7, 8.3 μ m) with immobilized aGPA (215 RU); $K_b=0.56\times10^4$ m⁻¹. C, shown is the interaction of VLRB.aGPA.23 with immobilized GPA (217 RU).

which compensated for a reduced enthalpy to achieve similar affinity.

VLRB.aGPA.23 bound the BG-H disaccharide \sim 2-fold less tightly than TF α (K_b = 0.96 \times 10⁴ M⁻¹) (Fig. 1, *E* and *F*) (Table 2). However, VLRB.aGPA.23 showed no detectable binding to galactose (not shown), which demonstrates the contribution of fucose at the non-reducing end of BG-H and of *N*-acetylgalactosamine at the reducing end of $TF\alpha$ to ligand recognition by this VLR.

To independently confirm our K_b measurements from ITC, we used SPR. In these experiments a biotinylated synthetic polyacrylamide glycoconjugate of $TF\alpha$ (TF α -PAA) was immobilized on a streptavidin-coated biosensor surface, over which soluble monomeric VLRB.aGPA.23 was then injected (Fig. 2*A*). Under equilibrium binding conditions, a K_b of 1.5×10^4 M⁻¹ was obtained, which is very similar to the K_b from ITC (2.21 \times 10^4 M⁻¹). The much higher effective affinity from SPR reported previously ($K_b = 1.3 \times 10^8 \,\text{m}^{-1}$) (11) may be explained by avidity effects. In that study we used a dimeric, not monomeric, form of VLR.aGPA.23 in which the VLR was fused to the Fc region of an antibody. In addition, the configuration of the SPR assay was reversed; multivalent $TF\alpha$ -PAA was flowed over immobilized dimeric (VLR.aGPA.23)₂-Fc protein (11), which allowed multipoint binding that produced a large avidity effect.

Values in parentheses refer to the highest resolution shell.

 b $R_{\text{merge}} = \Sigma |I_j - \langle I \rangle| / \Sigma I_j$, where I_j is the intensity of an individual reflection, and $\langle I \rangle$ is the average intensity of that reflection.
^c $R_{\text{work}} = \Sigma |I_j - |E_c| / \Sigma |F_o|$, where F_c is the calculated structure fa refinement.

We also compared the binding of VLRB.aGPA.23 to immobilized aGPA *versus* native GPA (Fig. 2, *B* and *C*). Whereas VLRB.aGPA.23 bound aGPA with $K_b = 0.56 \times 10^4$ M⁻¹, which is \sim 3-fold lower than its affinity for TF α , no binding to native GPA was detected, in agreement with previous results showing high selectivity for the desialylated protein (11).

*Overview of the VLRB.aGPA.23-TFα Complex-We deter*mined the crystal structure of VLRB.aGPA.23 bound to TF α -Ser to 2.2 Å resolution by molecular replacement using VLR-B.RBC36 (16) as a search model (Table 1; Fig. 3*A*). The root mean squared deviation in α -carbon positions for the four VLRB.aGPA.23 molecules in the asymmetric unit of the VLR-B.aGPA.23-TF α crystal was in the range of 0.14–0.25 Å, indicating close similarity. Unambiguous electron density corresponding to the Gal β 1–3GalNAc α moiety of TF α -Ser was found in the binding site, as evident from the $2F_o - F_c$ electron density map (Fig. 3*B*). However, no density was observed for the serine residue, suggesting flexibility due to lack of stable contacts with VLRB.aGPA.23. In agreement with this interpretation, TF α and TF α -Ser bound VLRB.aGPA.23 with very similar affinities and enthalpy changes (Table 2). The average temperature factor (*B*) for the Gal β 1–3GalNAc α portion of TF α -Ser was 34 \AA^2 , compared with 27 \AA^2 for main-chain atoms of the protein, indicating that the disaccharide is well ordered in the crystal.

We also determined the structure of VLRB.aGPA.23 in complex with the BG-H disaccharide Fuc α 1–2Gal β to 1.9 Å resolution (Table 1). The galactose moiety of BG-H was clearly defined in the electron density (Fig. 3*C*). However, no density was observed for fucose, even though this moiety contributes significantly to binding (see above). The average *B* factor for the galactose was 35 Å², compared with 20 Å² for main-chain atoms of VLRB.aGPA.23.

FIGURE 3. **Structure of the VLRB. aGPA.23-TF** α **complex.** A, a ribbon diagram of the VLRB.aGPA.23-TF α complex shows the concave antigen binding surface of the VLR solenoid. *Blue*, LRRNT; *orange*, LRR1, LRRV1–3, and LRRVe; *green*, CP; *red*, LRRCT. Carbons, nitrogens, and oxygens of TF are *cyan*, *blue*, and *red*, respectively. *B*, electron density from the final $2F_o - F_c$ map (contoured at 1 σ) of VLRB.aGPA.23-TF α at 2.2 Å resolution shows the Gal β 1– 3GalNAc α 1 moiety of TF α . *C*, electron density from the final 2 $F_o - F_c$ map (contoured at 1σ) of the VLRB.aGPA.23-BG-H complex at 1.7 Å resolution show of the galactose moiety of BG-H. RU, relative units.

VLRB.aGPA.23 adopts a horseshoe-shaped solenoid fold characteristic of other VLRs (Fig. 3*A*) (12, 16–19, 25). The structure comprises a 32-residue N-terminal LRR capping module (LRRNT), an 18-residue LRR1, four 24-residue LRRVs (LRRV1, LRRV2, LRRV3, and LRRVe), a 13-residue truncated LRR designated the connecting peptide (CP), and a 59-residue C-terminal LRR capping module (LRRCT). The inner, concave surface, through which VLRB.aGPA.23 binds $TF\alpha$, is composed of eight β -strands (two from LRRNT, five from LRRs, and one from CP), that assemble into a continuous β -sheet (Fig. 2A). Residues Glu-13, Val-14, and Asn-15 of LRRNT initiate an antiparallel β -strand that extends the continuous parallel β -sheet.

TABLE 2

Thermodynamic parameters for the binding of saccharides to VLRB.aGPA.23

The stoichiometry (*n*) values ranged from 0.989 to 1.09 with uncertainties from 0.4 to 10.0%. The values in parentheses represent uncertainties of fit. The temperature was $25 °C$.

The outer, convex surface of VLRB.aGPA.23 comprises an array of six loops and one α -helix. The region between the helices and strands constitutes the hydrophobic core of the VLR whose exposed ends are capped by LRRNT and LRRCT. In LRRNT, the characteristic four-cysteine motif of N-terminal LRR capping modules $(CX_nCX C X_nC)$ forms two sets of disulfides (Cys-3--Cys-9 and Cys-7--Cys-16); a similar motif in LRRCT gives rise to disulfides Cys-164--Cys-198 and Cys-166-- Cys-218. In their respective structures, the TF α and BG-H ligands are sandwiched between the concave surface of VLR-B.aGPA.23 and a protruding loop of LRRCT (residues 184– 190) (Fig. 3*A*), which corresponds to the highly variable insert of VLRs (12). This insert is absent from the LRRCTs of all other LRR-containing proteins, except platelet receptor glycoprotein $Iba(13)$.

The VLRB.aGPA.23-TF Interface—The VLRB.aGPA.23- $Ga1\beta1-3Ga1NAc\alpha$ complex buries a total solvent-accessible surface area of 270 \AA^2 , to which the LRR (LRRV1-3 and LRRVe), CP, and LRRCT modules contribute 67, 6, and 26%, respectively. The specificity of the interaction is mediated mainly by five hydrogen bonds, three of which involve the galactose moiety: between Asn-86 $N\delta$ 2 and galactose O6', between Asn-86 Oδ1 and *N*-acetylgalactosamine O4', between Ser-87 $O\gamma$ and *N*-acetylgalactosamine $O7'$, between Asp-134 O δ 1 and galactose O $4'$, and between Asp-134 O δ 2 and galactose O3 (Fig. 4*A* and *B*). Asn-86 and Ser-87 are located on LRRV2, and Asp-134 on LRRVe. Seven other residues (Trp-62, Trp-84, Gly-108, Cys-110, Gly-132, Trp-156, and Trp-187) stabilize the interaction with T_{α} via 53 van der Waals contacts. These residues, and in particular the four tryptophans, form a tight hydrophobic cage encasing the disaccharide that completely excludes buried water molecules (Fig. 4*C*). This cage together with the hydrogen bond network accounts for the exquisite glycan selectivity of VLRB.aGPA.23 (11). In addition, Trp-62 is positioned to sterically block the binding of oligosaccharides with extensions at the GalNAc end of the TF α disaccharide, further increasing selectivity (Fig. 4, *A* and *C*). Another key interaction with $TF\alpha$ involves Trp-187, whose indole is stacked parallel to the hydrophobic face of the galactose ring.

With the exception of Trp-187, which is in the LRRCT insert loop, all 10 TF α -contacting residues of VLRB.aGPA.23 are located on the β -strands of the LRR or CP modules: LRRV1 (Trp-62), LRRV2 (Trp-84, Asn-86, and Ser-87), LRRV3 (Gly-108 and Cys-110), LRRVe (Gly-132 and Asp-134), and CP (Trp-156). The antigen binding concave face of VLRB.aGPA.23, like that of other VLRs (12), is composed of three parallel ridges (designated R1, R2, and R3) associated with the beginning, middle, and end, respectively, of the β -strand of the LRR or CP

modules (Fig. 5). Each β -strand contains a 6-residue motif, $\frac{1}{1}Y(1/1)Y(1/Y^6)$ in which leugine or isolencine at positions 2 and *X*(L/I)XL*XX*⁶ , in which leucine or isoleucine at positions 2 and 4 form the hydrophobic core of the VLR, and the remaining four residues compose the three ridges: position 1 (R1), position 3 (R2), and positions 5 and 6 (R3). Sequence variability in VLRs is concentrated in R1–3 and in the LRRCT insert. In the VLR-B.aGPA.23-TF α complex, only R2 and R3, in addition to the LRRCT insert, contact the disaccharide (Fig. 5*A*), whereas in VLR-protein complexes, contacts are typically distributed across all three binding site ridges due to the larger size of the ligand (Fig. 5*B*).

The VLRB.aGPA.23-BG-H Interface—The VLRB.aGPA.23- $Fuc\alpha$ 1–2Gal β complex buries a total solvent-accessible surface area of 141 \AA^2 , to which the LRR (LRRV1–3 and LRRVe), CP, and LRRCT modules contribute 58, 10, and 31%, respectively. The specificity of the interaction is mediated mainly by three hydrogen bonds (Fig. 4*D*). Two of these hydrogen bonds, between Asp-134 $O\delta1$ and galactose $O4'$ and between Asp-134 O δ 2 and galactose O3', are found in the VLRB.aGPA.23-TF α complex (Fig. 4*B*). The third hydrogen bond, between Asn-86 N2 and galactose O1, is unique to the VLRB.aGPA.23-BG-H complex. Six other residues (Trp-84, Asn-86, Cys-110, Gly-132, Trp-156, and Trp-187), which also contact $TF\alpha$, stabilize the interaction with BG-H through 29 van der Waals contacts with the galactose (Fig. 4*D*).

Comparison with the VLRB.RBC36-BG-H2 Complex—A comparison of VLRB.aGPA.23 with VLRB.RBC36, which recognizes blood group H type 2 trisaccharide (BG-H2; $Fuc\alpha$ 1–2Gal β 1–4GlcNAc α) (16), showed high structural similarity (66% sequence identity; root mean squared difference 0.95 for 194 α -carbon atoms) (Fig. 6A). This similarity is remarkable given the vast size and diversity of VLR repertoires in terms of both length and sequence (15) and the fact that VLRB.aGPA.23 and VLRB.RBC36 were isolated from different lampreys by different laboratories using different techniques (11, 16). However, VLRB.aGPA.23 differs from VLRB.RBC36 at 8 of 10 TF α -contacting positions (Fig. 6*A*). Conversely, VLR-B.RBC36 differs from VLRB.aGPA.23 at 8 of 11 BG-H2-contacting positions. It is, therefore, not surprising that VLR-B.aGPA.23 exhibited no reactivity toward BG-H2 in glycan array profiling (11). Indeed, the only conserved interactions in the two complexes are two hydrogen bonds between Asp-134, present in both VLRs, and the common galactose moiety of $T F\alpha$ and BG-H2. These interactions impose a similar location and orientation on this galactose in the VLRB.aGPA.23-TF α and VLRB.RBC36-BG-H2 structures (Fig. 6*B*).

The main structural difference between VLRB.RBC36 and VLRB.aGPA.23 resides in their LRRCT inserts, which differ in

FIGURE 4. The VLRB.aGPA.23-TF α binding interface. A, shown is a close-up view of VLRB.aGPA.23 residues involved in recognizing the TF α disaccharide. Colors (including residue labels) are as in Fig. 3. The side chains of contacting residues are drawn in stick representation with nitrogens in *blue*, oxygens in *red*, and sulfur in yellow. Hydrogen bonds are indicated by *dotted lines*. A water molecule bound to galactose O3' is represented as a red sphere. B, shown is a schematic representation of interactions between VLRB.aGPA.23 and TFa. Residues making van der Waals contacts with TFa are indicated by *arcs with spokes radiating toward the ligand moieties* they contact. *C*, shown is tight packing of hydrophobic residues Trp-62, Trp-84, Trp-156, and Trp-187 around TF α , with their van der Waals radii drawn as surfaces. *D*, shown are schematic representations of interactions between VLRB.aGPA.23 and BG-H.

FIGURE 5. **Molecular architecture of the glycan-binding site of VLR-B.aGPA.23.** A, shown is a surface representation of $TF\alpha$ -contacting residues in the R2 (*cyan*) and R3 (*yellow*) ridges of VLRB.aGPA.23. The disaccharide does not interact with R1. *B*, shown is a surface representation of hen egg white lysozyme-contacting residues in R1 (*magenta*), R2, and R3 ridges of VLRB.2D (Protein Data Bank accession code 3G3A) (17).

both sequence and secondary structure. In VLRB.RBC36, the 10-residue insert forms a β -hairpin, whereas in VLRB.aGPA.23 the 9-residue insert is a loop whose overall shape differs markedly from that of the VLRB.RBC36 insert (Fig. 6*B*). In VLR-B.RBC36, Trp-204 is located at the end of the first β -strand of the LRRCT insert, before the β -hairpin turn, and interacts only

with the galactose of BG-H2. The corresponding residue of VLRB.aGPA.23, Trp-187, is located at the tip of the insert loop and interacts with both the galactose and *N*-acetylgalactosamine of $TF\alpha$, thereby covering much more of the ligand (Fig. 4*A*).

DISCUSSION

Carbohydrate recognition by proteins is a topic of considerable interest with practical implications for basic research and clinical applications once the specifics of the molecular recognition process are understood. For carbohydrate binding proteins to achieve high selectivity, they must meet the unique challenge of discriminating among a vast array of sugar structures arising from the stereochemistry of hydroxyl groups in monosaccharides and different sugar linkage possibilities. A substantial amount of thermodynamic and structural information is available on glycan binding by plant and animal lectins (24, 26) and by anti-carbohydrate antibodies (27–31). These studies have shown that lectins and antibodies recognize sugars through the stacking of aromatic residues against the sugar ring and hydrogen bonding of sugar hydroxyls to polar amino acid side chains.

VLRs, such as VLRB.aGPA.23, represent a new type of binding proteins with exceptional selectivity for carbohydrates, as demonstrated previously by glycan array profiling (11). Moreover, the affinity of VLRB.aGPA.23 for TF α measured here by ITC (K_b = 2.21 \times 10⁴ M⁻¹) was at the upper end of the spectrum for plant or animal lectins binding to disaccharide ligands (24). For example, the anti-HIV algal lectin griffithsin binds dimannoses with K_b values up to 2×10^4 M⁻¹ (32). More typically, lectins display \sim 10-fold lower affinity for disaccharides (24). Affinities in excess of 10^4 M^{-1} generally require longer oligosac-

FIGURE 6.**Comparison with the VLRB.RBC36-BG-H2 complex.** *A*, structure-based sequence alignment of VLRB.aGPA.23 and VLRB.RBC36 (3E6J) (16) is shown. Boundaries of the LRRNT, LRR1, LRRV1–3, LRRVe, CP, and LRRCT modules are indicated. *White characters on a red background* show strictly conserved residues. Residues that are well conserved are drawn in red and framed in *blue*. The remaining residues are *black*. Residues that contact TFa in the VLRB.aGPA.23-TFa complex are marked with *red triangles*. Residues that contact BG-H2 in the VLRB.RBC36-BG-H2 complex are marked with *blue triangles*. The paired *green numbers* (1– 4) indicate the bonded cysteine residues in the VLR structures. Sequence alignments were performed with the programs MultAlin and ESPript. *B*, the structure of the LRRCT inserts of VLRB.aGPA.23 (*orange*) and VLRB.RBC36 (*cyan*) shows interactions with TFα and BG-H2, respectively.

charides, which can interact with a more extended surface on the lectin (24, 26).

For anti-carbohydrate monoclonal antibodies, affinities in the range of 10^4 - 10^6 m^{-1} have been reported for tri-, tetra-, and pentasaccharides derived from *Salmonella* and *Shigella* lipopolysaccharide antigens (27–30). It should be noted, however, that these antibodies were obtained from mice immunized with the corresponding bacteria, whereas VLRB.aGPA.23 was isolated from lampreys that were not challenged with $TF\alpha(11)$. In addition, it should be possible to increase the affinity of glycanspecific VLRs such as VLRB.aGPA.23 by *in vitro* directed evolution, as in the case of VLRs reactive with the protein lysozyme, for which binding improvements of up to 1300-fold were achieved (33).

In common with other protein-carbohydrate interactions (24, 26), the binding of VLRB.aGPA.23 to all four glycans tested was characterized by a favorable enthalpy term, presumably due to the formation of hydrogen bonds and van der Waals contacts with the ligands (Table 2). In the case of $TF\alpha$ and TF α -Ser, the entropic contribution to the binding energy is slightly favorable (TF α -Ser) or slightly unfavorable (TF α), whereas for TF α -Thr and BG-H the entropy term makes a similar (BG-H) or greater (TF α -Thr) contribution to driving binding as the enthalpy term. This is somewhat atypical for sugar binding to proteins, where entropy is usually unfavorable due to loss of ligand conformational flexibility, and binding is enthalpically driven (24, 26). In this regard, structural studies of small

glycopeptides have shown that GalNA $c\alpha$ attached to serine and threonine prefer very different rotomer populations, both in solution (34) and *in silico* (35), which could affect binding thermodynamics.

The absence of electron density for fucose in the VLRB.aGPA.23-Fuc α 1–2Gal β structure is surprising, as fucose contributes significantly to binding. Although we do not have a satisfactory explanation for this result, the lack of density does not necessarily mean there is no interaction at all between fucose and VLR.aGPA.23 but only that the interaction may not be sufficiently stable to be visualized in the crystal. It is also conceivable that the conformational entropy of the $Fuc\alpha1 2$ Gal β ligand increases upon binding VLR.aGPA.23, thereby contributing favorably to the binding affinity. Although this may appear counterintuitive, NMR relaxation studies of galectin-3 have demonstrated that ligand binding increases the conformational entropy of the protein, which contributes favorably to the free energy of binding (36).

The architecture of the glycan-binding site of VLR-B.aGPA.23 differs markedly from those of lectins or antibodies, which typically consist of long grooves on the protein surface for accommodating oligosaccharide chains (24, 26, 28–30, 32). In the VLRB.aGPA.23-TF α complex, the disaccharide is sandwiched between the LRRCT insert loop and the concave surface of the VLR solenoid formed by the short β -strands of the LRR and CP modules. This parallel β -sheet does not lend itself to the construction of carbohydrate binding grooves of the type seen

Recognition of Thomsen-Friedenreich Antigen by Lamprey VLR

in lectins and antibodies (37), and none is present in VLR-B.aGPA.23 or VLRB.RBC36 (16). Based on the VLRB.aGPA.23- TF α structure, longer oligosaccharides with extensions at the reducing end of the TF α disaccharide (GalNAc α) would project perpendicularly across the β -strands, contacting additional LRR modules beyond LRRV1 (Fig. 6*A*). Although VLR-B.aGPA.23 contains only two additional N-terminal modules (LRRNT and LRR1), which would limit the potential contacting surface to perhaps a tetrasaccharide, other VLRs contain as many as six additional modules (12, 15). However, the curvature of the binding surface would increase progressively (37), requiring the oligosaccharide to bend to conform to the concavity of the rigid VLR solenoid to maintain contacts with the protein. By contrast, the carbohydrate binding surfaces of lectins and antibodies are generally flat or convex (24, 26, 28–30, 32). Despite these striking differences in binding site architecture, our structural and thermodynamic study of VLR-B.aGPA.23 has revealed how VLRs utilize the LRR scaffold to recognize glycans with an affinity and selectivity rivaling that of lectins and antibodies, making VLRs a highly promising class of natural glycan-binding proteins for basic research and clinical applications.

Acknowledgments—We thank Yili Li and Lu Deng for assistance with x-ray data collection and Mingming Gao for advice on data scaling and refinement.

REFERENCES

- 1. Varki, A., Kannagi, R., and Toole, B. P. (2009) in *Essentials of Glycobiology* (Varki, A., Cummings, R. D., Esko, J. D., Freeze, H. H., Stanley, P., Bertozzi, C. R., Hart, G. W., and Etzler, M. E., eds.) Chapter 44, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
- 2. Almogren, A., Abdullah, J., Ghapure, K., Ferguson, K., Glinsky, V. V., and Rittenhouse-Olson, K. (2012) Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy. *Front. Biosci. Schol. Ed.* **4,** 840–863
- 3. Powlesland, A. S., Hitchen, P. G., Parry, S., Graham, S. A., Barrio, M. M., Elola, M. T., Mordoh, J., Dell, A., Drickamer, K., and Taylor, M. E. (2009) Targeted glycoproteomic identification of cancer cell glycosylation. *Glycobiology* **19,** 899–909
- 4. Li, Q., Anver, M. R., Li, Z., Butcher, D. O., and Gildersleeve, J. C. (2010) GalNAcα1-3Gal, a new prognostic marker for cervical cancer. *Int. J. Cancer* **126,** 459–468
- 5. Manimala, J. C., Roach, T. A., Li, Z., and Gildersleeve, J. C. (2006) Highthroughput carbohydrate microarray analysis of 24 lectins. *Angew. Chem. Int. Ed. Engl.* **45,** 3607–3610
- 6. Manimala, J. C., Roach, T. A., Li, Z., and Gildersleeve, J. C. (2007) Highthroughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. *Glycobiology* **17,** 17C[en]23C
- 7. Sakai, K., Yuasa, N., Tsukamoto, K., Takasaki-Matsumoto, A., Yajima, Y., Sato, R., Kawakami, H., Mizuno, M., Takayanagi, A., Shimizu, N., Nakata, M., and Fujita-Yamaguchi, Y. (2010) Isolation and characterization of antibodies against three consecutive Tn-antigen clusters from a phage display library displaying human single-chain variable fragments. *J. Biochem.* **147,** 809–817
- 8. Hu, D., Tateno, H., Kuno, A., Yabe, R., and Hirabayashi, J. (2012) Directed evolution of lectins with a sugar-binding specificity for 6-sulfo-galactose. *J. Biol. Chem.* **287,** 20313–20320
- 9. Boltz, K. W., Gonzalez-Moa, M. J., Stafford, P., Johnston, S. A., and Svarovsky, S. A. (2009) Peptide microassays for carbohydrate recognition. *Analyst* **134,** 650–652
- 10. Sun, W., Du, L., and Li, M. (2010) Aptamer-based carbohydrate recognition. *Curr. Pharm. Des.* **16,** 2269–2278
- 11. Hong, X., Ma, M.Z., Gildersleeve, J.C., Chowdhury, S., Barchi, J. J. Jr., Mariuzza, R. A., Murphy, M. B., Mao, L., and Pancer, Z. (2013) Sugarbinding proteins from fish. Selection of high-affinity "lambodies" that recognize biomedically relevant glycans. *ACS Chem. Biol.* **8,** 152–160
- 12. Deng, L., Luo, M., Velikovsky, A., and Mariuzza, R. A. (2013) Structural insights into the evolution of the adaptive immune system. *Annu. Rev. Biophys.* **42,** 191–215
- 13. Rogozin, I. B., Iyer, L. M., Liang, L., Glazko, G. V., Liston, V. G., Pavlov, Y. I., Aravind, L., and Pancer, Z. (2007) Evolution and diversification of lamprey antigen receptors. Evidence for involvement of an AID-APOBEC family cytosine deaminase. *Nat. Immunol.* **8,** 647–656
- 14. Boehm, T. (2011) Design principles of adaptive immune systems. *Nat. Rev. Immunol.* **11,** 307–317
- 15. Boehm, T., McCurley, N., Sutoh, Y., Schorpp, M., Kasahara, M., and Cooper, M. D. (2012) VLR-based adaptive immunity. *Annu. Rev. Immunol.* **30,** 203–220
- 16. Han, B. W., Herrin, B. R., Cooper, M. D., and Wilson, I. A. (2008) Antigen recognition by variable lymphocyte receptors. *Science* **321,** 1834–1837
- 17. Velikovsky, C. A., Deng, L., Tasumi, S., Iyer, L. M., Kerzic, M. C., Aravind, L., Pancer, Z., and Mariuzza, R. A. (2009) Structure of a lamprey variable lymphocyte receptor in complex with a protein antigen. *Nat. Struct. Mol. Biol.* **16,** 725–730
- 18. Deng, L., Velikovsky, C. A., Xu, G., Iyer, L. M., Tasumi, S., Kerzic, M. C., Flajnik, M. F., Aravind, L., Pancer, Z., and Mariuzza, R. A. (2010) A structural basis for antigen recognition by the T cell-like lymphocytes of sea lamprey. *Proc. Natl. Acad. Sci. U.S.A.* **107,** 13408–13413
- 19. Kirchdoerfer, R. N., Herrin, B. R., Han, B.W., Turnbough, C. L. Jr., Cooper, M. D., and Wilson, I. A. (2012) Variable lymphocyte receptor recognition of the immunodominant glycoprotein of *Bacillus anthracis* spores. *Structure* **20,** 479–486
- 20. Storoni, L. C., McCoy, A. J., and Read, R. J. (2004) Likelihood-enhanced fast rotation functions. *Acta Crystallogr. D Biol. Crystallogr.* **60,** 432–438
- 21. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr. D Biol. Crystallogr.* **53,** 240–255
- 22. Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66,** 486–501
- 23. Pisano, A., Redmond, J. W., Williams, K. L., and Gooley, A. A. (1993) Glycosylation sites identified by solid-phase Edman degradation. *O*-Linked glycosylation motifs on human glycophorin A. *Glycobiology* **3,** 429–435
- 24. Dam, T. K., and Brewer, C. F. (2002) Thermodynamic study of lectincarbohydrate interactions by isothermal titration calorimetry. *Chem. Rev.* **102,** 387–429
- 25. Kim, H. M., Oh, S. C., Lim, K. J., Kasamatsu, J., Heo, J. Y., Park, B. S., Lee, H., Yoo, O. J., Kasahara, M., and Lee, J. O. (2007) Structural diversity of the hagfish variable lymphocyte receptors. *J. Biol. Chem.* **282,** 6726–6732
- 26. Imberty, A., Mitchell, E. P., and Wimmerová, M. (2005) Structural basis of high-affinity glycan recognition by bacterial and fungal lectins.*Curr. Opin. Struct. Biol.* **15,** 525–534
- 27. Brummell, D. A., Sharma, V. P., Anand, N. N., Bilous, D., Dubuc, G., Michniewicz, J., MacKenzie, C. R., Sadowska, J., Sigurskjold, B. W., and Sinnott, B. (1993) Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis. Role of the heavy-chain CDR3 residues. *Biochemistry* **32,** 1180–1187
- 28. Bundle, D. R., Eichler, E., Gidney, M. A., Meldal, M., Ragauskas, A., Sigurskjold, B. W., Sinnott, B., Watson, D. C., Yaguchi, M., and Young, N. M. (1994) Molecular recognition of a *Salmonella* trisaccharide epitope by monoclonal antibody Se155-4. *Biochemistry* **33,** 5172–5182
- 29. Sigurskjold, B. W., and Bundle, D. R. (1992) Thermodynamics of oligosaccharide binding to a monoclonal antibody specific for a *Salmonella* O-antigen point to hydrophobic interactions in the binding site. *J. Biol. Chem.* **267,** 8371–8376
- 30. Vyas, N. K., Vyas, M. N., Chervenak, M. C., Johnson, M. A., Pinto, B. M., Bundle, D. R., and Quiocho, F. A. (2002) Molecular recognition of oligosaccharide epitopes by a monoclonal Fab specific for *Shigella flexneri* Y lipopolysaccharide. X-ray structures and thermodynamics. *Biochemistry* **41,** 13575–13586

Recognition of Thomsen-Friedenreich Antigen by Lamprey VLR

- 31. Julien, J. P., Lee, P. S., and Wilson, I. A. (2012) Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. *Immunol. Rev.* **250,** 180–198
- 32. Moulaei T., Shenoy S. R., Giomarelli, B., Thomas, C., McMahon, J. B., Dauter, Z., O'Keefe, B. R., and Wlodawer, A. (2010) Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity. *Structure* **18,** 1104–1115
- 33. Tasumi, S., Velikovsky, C. A., Xu, G., Gai, S. A., Wittrup, K. D., Flajnik, M. F., Mariuzza, R. A., and Pancer, Z. (2009) High-affinity lamprey VLRA and VLRB monoclonal antibodies. *Proc. Natl. Acad. Sci. U.S.A.* **106,** 12891–12896
- 34. Corzana, F., Busto, J. H., Jiménez-Osés, G., García de Luis, M., Asensio,

J. L., Jiménez-Barbero, J., Peregrina, J. M., and Avenoza, A. (2007) Serine *versus* threonine glycosylation: the methyl group causes a drastic alteration on the carbohydrate orientation and on the surrounding water shell. *J. Am. Chem. Soc.* **129,** 9458–9467

- 35. Mallajosyula, S. S., and MacKerell, A. D. Jr. (2011) Influence of solvent and intramolecular hydrogen bonding on the conformational properties of *O*-linked glycopeptides. *J. Phys. Chem. B* **115,** 11215–11229
- 36. Akke, M. (2012) Conformational dynamics and thermodynamics of protein-ligand binding studied by NMR relaxation. *Biochem. Soc. Trans.* **40,** 419–423
- 37. Bella, J., Hindle, K. L., McEwan, P. A., and Lovell, S. C. (2008) The leucinerich repeat structure. *Cell. Mol. Life Sci.* **65,** 2307–2333

